Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants should self administer the preparation within 30 minutes and drink clear liquid according to local practice at the centre to prevent dehydration”In the company’s words, NCT04759885 on ClinicalTrials.gov
- Tested for
- Elective Colonoscopy
- Main trialPhase 2/3
- “The purpose of this dose finding/comparative efficacy study is to first single out the most appropriate dose of mannitol for bowel preparation (phase II) and, subsequently, demonstrate the non-inferiority of the efficacy of single dose mannitol vs standard split 2L PEG ASC (Moviprep®) (phase III) in bowel preparation for colonoscopy .”In the company’s words, NCT04759885 on ClinicalTrials.gov
Other drugs for Elective Colonoscopy
- InfigratinibQED Therapeutics, a BridgeBio company · Phase 2/3
- GaretosmabRegeneron · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 16 Jul 2021 | Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep® |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026